|
Second Site Approved for Phase 2 Covid-19 Trial
|
12 May 2023 at 10:40am
|
|
Commencement Phase 2 Covid-19 Clinical Trial
|
4 May 2023 at 9:40am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
27 April 2023 at 11:25am
|
|
Cleansing Notice
|
22 March 2023 at 3:10pm
|
|
Application for quotation of securities - BIT
|
22 March 2023 at 3:05pm
|
|
Completion of Phase 2 HIV-1 Clinical Trials
|
9 March 2023 at 10:25am
|
|
International Presentation of BIT225 COVID-19 Data
|
21 February 2023 at 10:30am
|
|
Half Yearly Report and Accounts
|
17 February 2023 at 1:15pm
|
|
Notification of cessation of securities - BIT
|
1 February 2023 at 6:05pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 January 2023 at 9:55am
|
|
CLEANSING NOTICE
|
25 January 2023 at 2:10pm
|
|
Application for quotation of securities - BIT
|
25 January 2023 at 1:50pm
|
|
Change of Director's Interest Notice
|
29 November 2022 at 1:30pm
|
|
Notification of cessation of securities - BIT
|
28 November 2022 at 3:40pm
|
|
Cleansing Notice
|
25 November 2022 at 12:20pm
|
|
Listed Options Information
|
25 November 2022 at 11:50am
|
|
Application for quotation of securities
|
25 November 2022 at 11:50am
|
|
Application for quotation of securities - BIT
|
25 November 2022 at 11:40am
|
|
Proposed issue of securities - BIT
|
24 November 2022 at 3:35pm
|
|
Rights Issue Closed
|
24 November 2022 at 10:25am
|
|
Supplementary Prospectus
|
24 November 2022 at 10:10am
|
|
Cancel - Proposed issue of securities - BIT
|
22 November 2022 at 9:30am
|
|
Appendix 3B
|
21 November 2022 at 6:05pm
|
|
$1.43M R&D rebate received
|
18 November 2022 at 11:50am
|
|
Results of Annual General Meeting
|
16 November 2022 at 4:00pm
|
|
Chairman's Address and Presentation to AGM
|
16 November 2022 at 11:05am
|
|
Presentation to Investors
|
11 November 2022 at 1:05pm
|
|
Clarification of Fractional Entitlements
|
7 November 2022 at 10:20am
|
|
Commencement of Rights Trading - BITRC
|
31 October 2022 at 12:25pm
|
|
Letter to Shareholders
|
31 October 2022 at 10:30am
|
|
Prospectus
|
27 October 2022 at 9:30am
|
|
Renounceable Issue
|
27 October 2022 at 9:25am
|
|
Proposed issue of securities - BIT
|
27 October 2022 at 8:55am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
24 October 2022 at 9:20am
|
|
Annual Report and Notice of Annual General Meeting
|
14 October 2022 at 11:30am
|
|
Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
|
4 October 2022 at 10:40am
|
|
Bit225 Covid-19 Human Study Commenced
|
14 September 2022 at 10:05am
|
|
BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
|
23 August 2022 at 12:40pm
|
|
Appendix 4G and Corporate Governance Statement
|
19 August 2022 at 4:20pm
|
|
Full Year Statutory Accounts and Appendix 4E
|
19 August 2022 at 4:20pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 July 2022 at 10:35am
|
|
POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM
|
30 May 2022 at 10:20am
|
|
BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS
|
2 May 2022 at 10:35am
|
|
Quarterly Cash Flow Report Appendix 4C
|
26 April 2022 at 1:50pm
|
|
Quarterly Activities Report
|
26 April 2022 at 1:50pm
|
|
$1.56M R&D Rebate Received
|
5 April 2022 at 10:15am
|
|
BIT225 Effectiveness Against COVID-19 in Animals
|
17 March 2022 at 11:30am
|
|
Half Yearly Report and Accounts
|
23 February 2022 at 4:30pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 January 2022 at 9:45am
|
|
Quarterly Appendix 4C Cash Flow Report
|
28 January 2022 at 9:05am
|
Biotron